Eli Lilly's Treasure Chest Overflows Weight Loss Drug Boom

A Pirate's Plunder: Lilly's Earnings Gold

Savvy? Seems Eli Lilly's found the Isla de Muerta of pharmaceutical fortunes. Their coffers are overflowing with more gold than I've ever seen in a Spanish galleon all thanks to these wondrous potions called Zepbound and Mounjaro. Forget finding the Fountain of Youth seems folks are chasing something a bit more…svelte. They're projecting revenues that'd make even Davy Jones envious somewhere between $80 billion and $83 billion by 2026. Now that's what I call a haul worthy of a pirate king.

Novo's Nordisk Navigational Nightmare

Now while Lilly's sailing on smooth seas their rivals at Novo Nordisk seem to be caught in a bit of a maelstrom. They're warning of sales and profit declines which sounds like walking the plank to me. Seems these deals with President Trump – aye the same one who probably wouldn't recognize a compass if it slapped him in the face – are causing a bit of a price kerfuffle. And it's all related to Alphabet's AI Gamble: Is Google Betting Big or Just Betting?. One wonders if these Nordisk lads should have consulted a better seer – or perhaps just not trusted a politician with promises of treasure. As I always say "The problem is not the problem. The problem is your attitude about the problem."

Medicare's Map to Riches

Ah Medicare. It's like finding a map to a buried treasure only instead of gold doubloons it's potential patients. Lilly's CEO Dave Ricks believes this government coverage of obesity treatments will be a "big multiplier" for their eligible pool. Sounds like a whole new market to plunder legally of course. One does wonder if they'll need a bigger ship to transport all the profits.

Pricey Potions and Pricing Plagues

Even with all the riches Lilly admits there's a bit of a pricing plague spreading. Global prices are expected to decline thanks to those Trump deals and direct to consumer rates. It's like bartering in Tortuga – always a negotiation always a risk of getting swindled. But fear not they plan to offset these losses with sheer volume. More prescriptions mean more gold even if each one is worth a little less. Clever girl.

Market Share Skirmishes

The seas of the pharmaceutical market are choppy and Lilly and Novo are locked in a battle for dominance. Lilly's managed to increase its share to a whopping 60.5% leaving Novo with a mere 39.1%. It's a bit like the East India Trading Company versus a humble pirate – only this time the pirate's winning. But as I always say "Why is the rum always gone?" Perhaps Novo should ask themselves the same question about their market share.

Fourth Quarter Forecasts and Fortunes

The numbers are in and they're staggering. Mounjaro raked in $7.41 billion a 110% increase. Zepbound a relative newcomer snagged $4.2 billion. Seems like the only thing growing faster than Lilly's profits is the demand for these miracle drugs. All this talk of numbers is giving me a headache – time for a flagon of rum to ease the pain.